NL-OMON37370已完成4 期
A prospective, randomized, double-blind parallel-arm, placebo-controlled study to assess the effects on ovarian activity of a combined oral contraceptive pill when preceded by the intake of ellaOne® (ulipristal acetate 30 mg) or placebo. - Quickstart combined OAC after emergency contraception
HRA Pharma0 个研究点目标入组 45 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- healthy women
- •- age 18-35 years
- •- not at risk for pregnancy
排除标准
- •- contraindication for use of combined oral contraceptives (e.g. history of venous or arterial thromboembolic disease
- •- clinically relevant findings (physical and gynecological examination, blood pressure)
- •- irregular mentrual cycle
- •- intake of medication thought to interact with ellaOne or combined oral contraceptives
研究者
相似试验
进行中（未招募）
不适用
ot applicableContraceptionEUCTR2011-005573-23-NLaboratoire HRA Pharma85
进行中（未招募）
不适用
ot applicableContraceptionEUCTR2011-005573-23-SEaboratoire HRA Pharma85
进行中（未招募）
不适用
ot applicableContraceptionEUCTR2011-005573-23-GBaboratoire HRA Pharma85
Unknown
不适用
A clinical study on effects of Sugaheal® in patients with Type 2 Diabetes MellitusCTRI/2013/01/003314Indus Biotech Private Limited
招募中
1 期
To investigate efficacy, pharmacodynamics, and safety of BC 007 in participants with long COVIDEUCTR2022-003452-14-FIBerlin Cures GmbH114